Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide

Diabetes, Obesity and Metabolism

Volumn 10, Issue 7, 2008, Pages 593-596

  Horowitz, Michael ^a   Vilsboll T ^b   Zdravkovic, M ^c   Hammer, M ^c   Madsbad, S ^d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FISHER EXACT TEST; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; INDIGESTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUESTIONNAIRE; RATING SCALE; SELF REPORT; SEX RATIO;

EID: 45449114603     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00861.x     Document Type: Article

References (8)

1. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-711.
2. Vilsbøll T, Zdravkovic M, Le Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
3. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study. Diabetes 2006; 55 (Suppl. 1): A465.
4. Vilsbøll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue improves beta-cell function and arginine-stimulated insulin secretion at hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2007: DOI: 10.111/j.1464-5491.2007.02333.x
5. Madsbad S, Schmitz O, Ranstam J, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342.
6. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. NN2211-1499 study group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006; 114: 417-423.
7. Dimenas E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28: 681-687.
8. Dimenas E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-1052.